The inhibitory subunit of cardiac troponin (cTnI) is modified by arginine methylation in the human heart

Abstract

BackgroundThe inhibitory subunit of cardiac troponin (cTnI) is a gold standard cardiac biomarker and also an essential protein in cardiomyocyte excitation-contraction coupling. The interactions of cTnI with other proteins are fine-tuned by post-translational modification of cTnI. Mutations in cTnI can lead to hypertrophic cardiomyopathy. Methods and ResultsHere we report, for the first time, that cTnI is modified by arginine methylation in human myocardium. Using Western blot, we observed reduced levels of cTnI arginine methylation in human hypertrophic cardiomyopathy compared to dilated cardiomyopathy biopsies. Similarly, using a rat model of cardiac hypertrophy we observed reduced levels of cTnI arginine methylation compared to sham controls. Using mass spectrometry, we identified cTnI methylation sites at R74/R79 and R146/R148 in human cardiac samples. R146 and R148 lie at the boundary between the critical cTnI inhibitory and switch peptides; PRMT1 methylated an extended inhibitory peptide at R146 and R148 in vitro. Mutations at R145 that have been associated with hypertrophic cardiomyopathy hampered R146/R148 methylation by PRMT1 in vitro. H9c2 cardiac-like cells transfected with plasmids encoding for a methylation-deficient R146A/R148A cTnI protein developed cell hypertrophy, with a 32% increase in cell size after 72 h, compared to control cells. DiscussionOur results provide evidence for a novel and significant cTnI post-translational modification. Our work opens the door to translational investigations of cTnI arginine methylation as a biomarker of disease, which can include e.g. cardiomyopathies, myocardial infarction and heart failure, and offers a novel way to investigate the effect of cTnI mutations in the inhibitory/switch peptides. Abbreviations: Arginine methylation (ArgMe), collision induced dissociation (CID), dilated cardiomyopathy (DCM), hypertrophic cardiomyopathy (HCM), matrix-assisted laser desorption ionisation -time of flight (MALDI-TOF), protein arginine methyltransferases (PRMTs), Sadenosyl-L-methionine (SAM).

RETRACTED ARTICLE: Anti-inflammatory effect of up-regulated microRNA-221-3p on coronary heart disease via suppressing NLRP3/ASC/pro-caspase-1 inflammasome pathway activation

“…It has been suggested previously that MDA is used as a biomarker of lipid peroxidation in biological samples [29]. cTnI is a gold standard myocardial biomarker, and it is also an important protein in cardiomyocyte excitation-contraction coupling [30]. A study has The apoptosis rate of cardiomyocytes in each group.…”

PRMT5 Prevents Cardiomyocyte Hypertrophy via Symmetric Dimethylating HoxA9 and Repressing HoxA9 Expression

“…The PRMT family members have pivotal roles in regulating heart diseases (Beltran-Alvarez et al, 2013;Pyun et al, 2018;Onwuli et al, 2019). Among all these PRMTs, PRMT5 is an arginine methyltransferase responsible for symmetric dimethylation (Branscombe et al, 2001), and is closely involved in cardiac hypertrophy according to our previous observations (Chen et al, 2014;Cai et al, 2020).…”

Protective role of emodin in rats with post-myocardial infarction heart failure and influence on extracellular signal-regulated kinase pathway

“…CTnI is an ideal cardiomyocyte-specific marker, and also one of the crucial indicators for the clinical diagnosis of myocardial injury. It is a regulatory protein that only exists in the myocardium and plays an essential role in myocardial contraction and relaxation [ 15 ]. Recently, mitochondrial production has been closely related to the regulation of mitochondrial functions, of which PGC-1 may be a key regulator.…”